

# Ronald Witteles

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3852810/publications.pdf>

Version: 2024-02-01

34  
papers

2,691  
citations

759233

12  
h-index

434195

31  
g-index

34  
all docs

34  
docs citations

34  
times ranked

2720  
citing authors

#	ARTICLE	IF	CITATIONS
1	Developing Therapy for Transthyretin Amyloidosis. American Journal of Medicine, 2022, , .	1.5	4
2	High-Throughput Precision Phenotyping of Left Ventricular Hypertrophy With Cardiovascular Deep Learning. JAMA Cardiology, 2022, 7, 386.	6.1	63
3	Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121009038.	3.9	6
4	Efficacy and safety of tafamidis doses in the <scp>Tafamidis in Transthyretin Cardiomyopathy Clinical Trial</scp> (<scp>ATTRâ€œACT</scp>) and longâ€œterm extension study. European Journal of Heart Failure, 2021, 23, 277-285.	7.1	103
5	Reply to the letter regarding the article â€œEfficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (<scp>ATTRâ€œACT</scp>) and longâ€œterm extension studyâ€œ™. European Journal of Heart Failure, 2021, 23, 1057-1058.	7.1	1
6	Avoiding Catastrophe. Circulation: Heart Failure, 2021, 14, e008225.	3.9	9
7	Mitochondria-Rich Extracellular Vesicles Rescue Patient-Specific Cardiomyocytes From Doxorubicin Injury. JACC: CardioOncology, 2021, 3, 428-440.	4.0	42
8	Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey. JACC: CardioOncology, 2021, 3, 537-546.	4.0	21
9	Misconceptions and Facts About Cardiac Amyloidosis. American Journal of Cardiology, 2021, 160, 99-105.	1.6	7
10	Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival. Blood, 2021, 138, 2720-2720.	1.4	4
11	Ibrutinib-associated atrial fibrillation treatment with catheter ablation. HeartRhythm Case Reports, 2021, 7, 713-716.	0.4	4
12	Graded Renal Response Criteria for Light Chain (AL) Amyloidosis. Blood, 2021, 138, 2721-2721.	1.4	5
13	Free Light-Chain Levels in Patients with Transthyretin Amyloid Cardiomyopathy in Attr-ACT. Blood, 2021, 138, 3787-3787.	1.4	2
14	TNF-alpha inhibition for the treatment of cardiac sarcoidosis. Seminars in Arthritis and Rheumatism, 2020, 50, 546-552.	3.4	27
15	Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Family Practice, 2020, 21, 198.	2.9	60
16	Outcomes By Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from Andromeda. Blood, 2020, 136, 44-45.	1.4	5
17	Portable Ultrasound Device Usage and Learning Outcomes Among Internal Medicine Trainees: A Parallelâ€œGroup Randomized Trial. Journal of Hospital Medicine, 2020, 15, 154-159.	1.4	13
18	Genomics in medicine: a novel elective rotation for internal medicine residents. Postgraduate Medical Journal, 2019, 95, 569-572.	1.8	5

#	ARTICLE	IF	CITATIONS
19	Thrombophilia testing in the inpatient setting: impact of an educational intervention. BMC Medical Informatics and Decision Making, 2019, 19, 167.	3.0	1
20	Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circulation: Heart Failure, 2019, 12, e006075.	3.9	312
21	Serial Cardiac FDG-PET for the Diagnosis and Therapeutic Guidance of Patients With Cardiac Sarcoidosis. Journal of Cardiac Failure, 2019, 25, 307-311.	1.7	41
22	Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine, 2018, 379, 1007-1016.	27.0	1,558
23	Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry). American Journal of Cardiology, 2017, 120, 1381-1386.	1.6	12
24	A high value care curriculum for interns: a description of curricular design, implementation and housestaff feedback. Postgraduate Medical Journal, 2017, 93, 725-729.	1.8	8
25	Genotype and Phenotype of Transthyretin Cardiac Amyloidosis. Journal of the American College of Cardiology, 2016, 68, 161-172.	2.8	338
26	A resident-created hospitalist curriculum for internal medicine housestaff. Journal of Hospital Medicine, 2016, 11, 646-649.	1.4	8
27	Patient Outcomes when Housestaff Exceed 80 Hours per Week. American Journal of Medicine, 2016, 129, 993-999.e1.	1.5	16
28	Prevalence and Financial Impact of Inappropriate Thrombophilia Testing in the Inpatient Hospital Setting: A Retrospective Analysis. Blood, 2016, 128, 2330-2330.	1.4	1
29	Hematologic Responses and Cardiac Organ Improvement in Patients with Heavily Pretreated Cardiac Immunoglobulin Light Chain (AL) Amyloidosis Receiving Daratumumab. Blood, 2016, 128, 4525-4525.	1.4	8
30	Incidence and severity of cardiotoxicity in metastatic renal cell carcinoma (RCC) patients treated with targeted therapies.. Journal of Clinical Oncology, 2012, 30, 4610-4610.	1.6	2
31	AL Amyloidosis and Concomitant Myeloma: Time to Reconsider Assumptions. Blood, 2010, 116, 4044-4044.	1.4	0
32	A Pilot Study of Melphalan, Lenalidomide and Dexamethasone In AL Amyloidosis: Interim Results. Blood, 2010, 116, 1946-1946.	1.4	0
33	AL Amyloidosis: Prognosis of Cardiac Involvement Reconsidered.. Blood, 2009, 114, 4872-4872.	1.4	0
34	Premature ventricular contractions causing pacemaker-mediated tachycardia: A failure of postventricular atrial refractory period after premature ventricular contraction extension?. Heart Rhythm, 2005, 2, 1389-1390.	0.7	5